Watch JAZZ. Know when insiders buy.
One email the day a filing lands. Free.
Work order
29
FLAG · insiders 25, shorts 32
Insiders, 90 days
−$20.7M
net selling · 0 buys, 7 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $16.1BP/E 16.9DIV YIELD —FCF YIELD 9.90%REV TTM $4.6B +12.6%NET INCOME $940.8MNET DEBT $2.7B52W 125.22 – 261.62SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.2B | +15.5% | — | $248.2M | $192.8M | — | 2.78 | $415.7M | $18.1M | $397.6M | Aug 3 |
| Q1 2026 · Mar 31 | $1.1B | +19.1% | — | $336.6M | $293.1M | — | 4.43 | $408.2M | $19.7M | $388.5M | Aug 3 |
| Q4 2025 · Dec 31derived | $1.2B | +10.1% | — | $254.5M | $203.5M | +6.5% | 3.34 | $362.5M | $16.7M | $345.8M | Feb 24 |
| Q3 2025 · Sep 30 | $1.1B | +6.7% | — | $57.5M | $251.4M | +16.9% | 4.08 | $474.7M | $15.2M | $459.4M | Nov 5 |
| Q2 2025 · Jun 30 | $1B | +2.1% | — | −$686.4M | −$718.5M | −526.2% | -11.74 | $88.8M | $12.9M | $75.9M | Aug 3 |
| Q1 2025 · Mar 31 | $897.8M | −0.5% | — | −$55.9M | −$92.5M | — | -1.52 | $429.8M | $13.9M | $415.9M | Aug 3 |
| Q4 2024 · Dec 31derived | $1.1B | +7.5% | — | $190.8M | $191.1M | +103.0% | 3.02 | $398.6M | $13.3M | $385.3M | Feb 24 |
| Q3 2024 · Sep 30 | $1.1B | +8.5% | — | $260.2M | $215.1M | +46.5% | 3.42 | $398.7M | $10.8M | $388M | Nov 5 |
| Q2 2024 · Jun 30 | $1B | — | — | $199.4M | $168.6M | — | 2.49 | $331.4M | $7.1M | $324.3M | Nov 5 |
| Q1 2024 · Mar 31 | $902M | — | — | $66.2M | −$14.6M | — | -0.23 | $267.2M | $6.9M | $260.3M | Nov 5 |
| Q4 2023 · Dec 31derived | $1B | — | — | $122.5M | $94.2M | — | 1.43 | $167.3M | $10.1M | $157.2M | Feb 24 |
| Q3 2023 · Sep 30 | $972.1M | — | — | $172.4M | $146.8M | — | 2.14 | $307.2M | $4.3M | $302.9M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $4.3B | — | −$430.2M | −$356.1M | -8.3% | -5.84 | $1.4B | $58.8M | $1.3B | $125M | — |
| FY2024 · to Dec 31 | $4.1B | — | $716.6M | $560.1M | 13.8% | 8.65 | $1.4B | $38.1M | $1.4B | $311.4M | — |
| FY2023 · to Dec 31 | $3.8B | — | $578.6M | $414.8M | 10.8% | 6.10 | $1.1B | $24M | $1.1B | $269.8M | — |
| FY2022 · to Dec 31 | $3.7B | — | −$65.5M | −$224.1M | -6.1% | -3.58 | $1.3B | $29M | $1.2B | $54K | — |
| FY2021 · to Dec 31 | $3.1B | — | $170.3M | −$329.7M | -10.7% | -5.52 | $778.5M | $27.6M | $750.9M | $0 | — |
| FY2020 · to Dec 31 | $2.4B | — | $378.1M | $238.6M | 10.1% | 4.22 | $899.6M | $15M | $884.6M | $146.5M | — |
Every number comes from Jazz Pharmaceuticals plc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.